Anticoagulation and Covid-19: A Meta-Analysis

Abstract

To investigates the association between the use of anticoagulation and mortality among hospitalized patients with COVID-19 in order to provide clinical insights. METHODS: An electronic search was conducted in Pubmed, Scopus, and Medrxiv (preprint articles), using the search strategy included all MeSH terms and free keywords found for "coronavirus 2019" OR "COVID-19" OR "2019-nCoV" or "SARS-CoV-2", AND "anticoagulation" OR "heparin" OR "enoxaparin" OR "apixaban" OR "rivaroxaban" between 2019 and present time without language restriction. The title, abstract, and full text of all documents captured with these search criteria were scrutinized, and those reporting the rate of anticoagulation in COVID-19 patients were included in this meta-analysis. The reference list of these identified studies was also analyzed (forward and backward citation tracking) for detection gother potential eligible articles. A meta-analysis was performed with Comprehensive Meta-Analysis software (version 3.3.070) in accordance with the PRISMA guidelines.

Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis

“…Prophylactic dosages of anticoagulant treatment may be more suitable for patients with COVID-19. 24 Traditionally, anticoagulant use, mainly heparin, reduced all-cause mortality in COVID-19 patients during hospitalization. 12 However, compared with prophylactic anticoagulation, therapeutic anticoagulation in hospitalized COVID-19 patients not only was not associated with a reduction in in-hospital mortality but also increased the risk of major bleeding.…”